Prefrontal Gene Networks Predict Fentanyl Escalation in Rat Models

The rapid proliferation of illicitly manufactured fentanyl has fundamentally altered the landscape of opioid use disorder (OUD), with urine drug testing positivity for the synthetic opioid increasing by 34% to 138% during the COVID-19 pandemic [1, 2]. While buprenorphine and methadone remain the gold standard for management, clinicians frequently encounter patients who struggle with rapid escalation of intake; for instance, those with baseline fentanyl use may achieve opioid-negative urine samples only 18.8% of the time when treated with standard sublingual buprenorphine-naloxone [3, 4, 5]. Standard risk assessments often rely on socio-structural factors or a history of nonfatal overdose, which is reported by 58% of treatment-seeking adults with non-heroin OUD, yet these markers do not fully account for the biological vulnerability driving the transition to compulsive seeking [6]. Understanding the neurobiological mechanisms that differentiate susceptible individuals is critical, particularly the role of the neuroimmune system (the network of glial cells, such as microglia and astrocytes, that regulate neuroinflammation and synaptic function) [7]. A new study now offers insights into the behavioral and transcriptomic markers (the complete set of RNA transcripts produced by the genome, which reflects real-time gene expression) that may predict the escalation of fentanyl consumption.